author-photo

Cordula Zeller

Boehringer Ingelheim

40

Papers

2040

Citations

Citation Trend

Filter By

Papers (27) Sort By

Journal Conference Others

Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial

2021 European Journal of Heart Failure
Show All
- Source
- Cite
- Save
Citations (0)
P002. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

2021 Heart & Lung
Show All
- Source
- Cite
- Save
Citations (0)
Cardiovascular and Kidney Outcomes with Empagliflozin in Heart Failure

2021
Show All
- Source
- Cite
- Save
Citations (0)
Effect of Empagliflozin on Worsening Heart Failure Events in Patients with Heart Failure and a Preserved Ejection Fraction: The EMPEROR-Preserved Trial.

2021 Circulation
Show All
- Source
- Cite
- Save
Citations (7)
Empagliflozin and Major Renal Outcomes in Heart Failure.

2021 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (6)
Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME.

2020 Esc Heart Failure
Show All
- Source
- Cite
- Save
Citations (7)
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.

2020 European Heart Journal
Show All
- Source
- Cite
- Save
Citations (24)
Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.

2020 Circulation
Show All
- Source
- Cite
- Save
Citations (52)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

2020 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (798)
EMPAGLIFLOZIN IS ASSOCIATED WITH A LOWER RISK OF POST-ACUTE HEART FAILURE RE-HOSPITALIZATION AND MORTALITY: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL

2019 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (4)